Cancer diagnostics, therapeutics, and drug discovery associated with macropinocytosis
The present invention is directed to methods of inhibiting both proliferation and survival of cancer cells and for treating a subject having cancer. The present invention is further directed to methods of diagnosing cancer in a subject and identifying cancer therapeutics.
1. A method comprising:
selecting a subject having cancer;
administering to the selected subject an agent selected from the group consisting of dextran, albumin, poly(beta-amino ester) nanoparticles, polyethylenimine-alt-poly(ethylene glycol) copolymer nanoparticles, and lipid nanoparticles;
detecting the presence of the agent in cells of the subject; and
quantifying the presence of the agent in cancerous cells and non-cancerous cells of the subject.
2. The method according to claim 1 , wherein the selected subject has an oncogene mediated cancer.
3. The method according to claim 2 , wherein the oncogene mediated cancer is selected from the group consisting of ras-mediated cancer, src-mediated cancer, and EGFR-mediated cancer.
4. A method according to claim 1 , wherein the selected subject has a cancer selected from the group consisting of pancreatic cancer, lung cancer, colorectal cancer, thyroid cancer, liver cancer, and leukemia.
5. The method according to claim 1 , wherein the agent is labeled with a fluorescent label, a bioluminescent label, or a radioisotope.
6. The method according to claim 1 , further comprising: administering a chemotherapeutic agent to the subject based on said quantifying.
7. The method according to claim 1 , further comprising: administering a macropinocytosis inhibitor to the subject based on said quantifying, wherein said macropinocytosis inhibitor is selected from the group consisting of wortmannin, LY294002, amiloride, and an analogue of amiloride.